CEL-SCI Phase 3 Multikine at ESMO: 45 responses, all in treatment group (1 in 100B chance), >3x OS benefit

CEL SCI CORP

45 RECIST neoadjuvant responses including 5 complete; all exclusive to Multikine groups (1 in 100 billion chance).
Overall survival >3x longer for responders vs non-responders.
Early tumor response (pre-surgery) noted only in Multikine groups, not control; prognostic and predictive for OS.
Biomarker analysis: low tumor PDL1, high immune cell density, specific ratios predict Multikine efficacy.
Data from the largest Phase 3 study ever in newly diagnosed locally advanced head and neck cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.